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S U M M A R Y
Hantaviruses infect their reservoir hosts and humans, but the infection only causes disease in humans. In
Asia and Europe (the Old World), the hantaviruses usually cause haemorrhagic fever with renal
syndrome (HFRS). This article summarizes the current understanding of hantavirus epidemiology, as
well as the clinical manifestations, pathogenesis, renal pathology, diagnosis, treatment, and prevention
of HFRS. Moreover, the spatiotemporal distribution of HFRS was analysed based on the latest data
obtained from the Chinese Centre for Disease Control and Prevention, for the period January 2004 to April
2015, to provide valuable information for the practical application of more effective HFRS control and
prevention strategies in China.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Haemorrhagic fever with renal syndrome (HFRS), a rodent-
borne infectious disease caused by hantaviruses, is clinically
characterized in humans by fever, haemorrhage, headache,
abdominal pain, and acute kidney damage. HFRS occurs primarily
in the Old World and is endemic all over China, with the exception
of the Taiwan region.1,2 China has the highest incidence of HFRS,
accounting for approximately 90% of HFRS cases globally in the last
few decades. During recent decades, the incidence of HFRS has
ﬂuctuated, but it has remained one of the top nine communicable
diseases in mainland China. This study was performed to review
what is known about HFRS and to identify its epidemiological
distribution in China.
2. HFRS-associated hantavirus infection
Hantaviruses are single-stranded, enveloped RNA viruses of the
Bunyaviridae family. They cause two human syndromes, hantavi-
rus cardiopulmonary syndrome (HCPS) in the Americas and HFRS
in Europe and Asia.3 Seven sero/genotypes of HFRS-associated* Corresponding author. Tel.: +86 0516 83956891; fax: +86 0516 83840486.
E-mail address: slpku@163.com (L. Sun).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hantaviruses have been identiﬁed (Hantaan, Dobrava, Saaremaa,
Seoul, Amur, Puumala, and Far East), and two of these, Hantaan
virus (HTNV) and Seoul virus (SEOV), are the major causative
agents of HFRS in China.4
Hantaviruses are unexpectedly stable in air and can survive >10
days at room temperature and >18 days at 4 8C and 20 8C.5,6
Hantaviruses are mainly carried by rodents, insectivores, and bats.
They are transmitted to humans via inhalation of virus-contami-
nated aerosols of excreta and secreta, via contaminated food, and
rarely, via rodent bites.7 Hantavirus infection has also been
reported in several species of domestic animals, such as cats, dogs,
pigs, and rabbits.8 The survival of hantaviruses depends on the
maintenance of persistent infection within their reservoir hosts.9
Thus, hantavirus emergence in humans depends on the following
factors: (1) the external environmental factors including temper-
ature, rainfall, relative humidity, land use, the normalized
difference vegetation index (NDVI), the temperature vegetation
dryness index (TVDI), and elevation, which play signiﬁcant roles in
reservoir host density and the level of exposure to infectious
viruses;1,10,11 (2) the frequency of contact between the human and
rodent populations, which is associated with human activities,
living conditions, working conditions, and urbanization;12 and (3)
the proportion of infections resulting in HFRS, which may be due to
the susceptibility of humans to hantaviruses and may be
inﬂuenced by population immunity and vaccination.3,13ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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The clinical picture of HFRS is characterized by acute renal
failure, accompanied by haemorrhage and ﬂu-like symptoms, such
as fever, headache, and abdominal/back/orbit pain.14 Kidney
manifestations are characterized predominantly by massive
proteinuria, haematuria, and a rapid decline in glomerular
ﬁltration rate (GFR), resulting in oedema, disorder of electrolytes
and acid–base balance, and the need for dialysis.15 Severe
complications may involve multiple systems. In the neurological
system, meningoencephalitis, acute disseminated encephalomy-
elitis, generalized seizures, Guillain–Barre´ syndrome, urinary
bladder paralysis, and seizures have been reported. In the
cardiopulmonary system, shock, perimyocarditis, and pulmonary
oedema may develop. Disseminated intravascular coagulopathy,
multiple bleedings, pancreatitis, and multiorgan failure have also
been observed, all of which may lead to a lethal outcome.16
Classic clinical HFRS occurs in ﬁve phases: febrile phase (3–7
days), hypotensive phase (hours to 2 days), oliguric phase (3–7
days), diuretic phase (polyuria) (days to weeks), and convalescent
phase (2–3 months). Long-term outcomes after HFRS show a much
higher prevalence of renal tubular dysfunction, glomerular
hyperﬁltration, chronic glomerulonephritis, hypertension, acute
myocardial infarction, and stroke compared with the general
population.16–18
4. Pathogenesis of HFRS
Humans are not a natural reservoir and, therefore, become
infected when they come into contact with the excreta of reservoir
hosts, such as rodents. Infections can result in serial diseases, and
the pathogenesis and outcomes vary with the different species of
hantavirus. The hallmarks of HFRS are increased vascular
permeability, thrombocytopenia, coagulopathy, and haemorrhagic
manifestations. The molecular mechanisms of HFRS are not well
understood. A complex interplay between hantaviruses, host
immune responses, and endothelial cells has emerged as a
common theme. Hantavirus infection directly or indirectly leads
to the activation of signalling pathways and the dysregulation of
immune cells, such as CD4+ T-cells and CD8+ T-cells. The
inﬂammatory response leads to the activation of the complement
system, the formation of circulating immune complexes, and the
secretion of multiple proinﬂammatory cytokines. These cytokines
promote endothelial cell dysfunction and capillary leakage.14,19
Haemorrhage is common in HFRS. The coagulopathy appears to be
a thrombosis–ﬁbrinolysis imbalance combined with platelet
deposition and dysfunction. Severe thrombocytopenia is associat-
ed with a more severe course of the disease in HFRS.20,21
5. Renal pathology of HFRS
Increased vascular permeability in HFRS is indicated by
widespread capillary engorgement, focal haemorrhage, and
interstitial oedema in the renal medulla. Hantavirus nephropathy
is an uncommon aetiology of acute renal failure due to hantavirus
infection. Light microscopy of renal biopsies from hantavirus
nephropathy patients shows interstitial haemorrhage and oedema,
acute tubular necrosis, inﬂammation of the renal microvessels,
cortical peritubular capillaritis, and medullary vasa recta inﬂam-
mation, with minor changes in the glomeruli. Immunohistochemi-
cal studies have shown the deposition of circulating immune
complexes and activation of the complement system. Furthermore,
anti-CD3, anti-CD68, and anti-CD34 antibodies have positively
highlighted the involvement of T-cells and macrophages in renal
microvascular inﬂammation.22 Electron microscopy has revealed
podocyte foot process effacement, which indicates that hantavirusinfection might perturb podocyte integrity, resulting in glomerular
proteinuria. These alterations of acute tubular necrosis and
podocytes may be reversible and transient and may resolve
within weeks to months.23
6. Diagnosis and biomarkers of HFRS
The diagnosis of hantavirus infections in humans is based on
clinical and epidemiological information as well as laboratory
tests. Laboratory testing should be performed for patients with
fever of unknown origin, thrombocytopenia, renal failure, or
respiratory distress, who live in hantavirus disease-endemic
regions. The laboratory diagnosis of hantavirus infection is based
mainly on three primary categories of test: serology, molecular
methods, and immunochemistry (Table 1).24–38 The most practical
approach is a serological test to detect IgM/IgG antibodies of the
three structural hantavirus proteins (Gn, Gc, and N) using ELISAs.
Real-time RT-PCR is a sensitive tool for the early detection of
hantavirus RNA that can detect hantavirus RNA prior to the
appearance of IgM antibodies. Therefore, the combination of IgM/
IgG ELISAs and RT-PCR is a sensitive and desirable approach for the
laboratory diagnosis of hantavirus infection. Immunohistochem-
istry is of great utility for identifying viral antigens in tissues,
particularly in fatal cases without other types of sample. Virus
isolation from human samples is rare, and it is not an option in the
diagnosis of human hantavirus infection.
Many new biomarkers have been reported to be associated with
a severe course of hantavirus infection. Several examples that have
been reported recently are listed here. CD163 is expressed by
monocytes/macrophages in response to inﬂammatory stimuli. The
level of plasma soluble CD163 in HFRS patients has been found to
increase at fever onset and to peak in the oliguric phase, positively
correlating with the severity and progression of disease.39,40 The
level of high mobility group box protein 1 (HMGB-1) has been
found to correlate positively with the white blood cell count and
blood urea nitrogen (BUN) and to correlate negatively with the
platelet count, albumin, and uric acid (UA). The HMGB-1 level has
been found to be predictive of the prognosis in HFRS patients.41
The serum decoy receptor 3 (DcR3) level has been shown to be
positively correlated with tumour necrosis factor alpha (TNF-a)
and to peak during the oliguric phase, reﬂecting the severity of
kidney damage, characterized by elevated BUN, creatinine, and
proteinuria.42 Interleukin 21 (IL-21) has been shown to stimulate
T-cell and B-cell responses in the pathogenesis of HFRS. IL-21
begins to increase in the fever phase, peaks in the oliguric phase,
and is associated with the disease severity of HFRS.43 As one of the
vascular permeability cytokines, the serum level of vascular
endothelial growth factor (VEGF) has been reported to be
persistently elevated throughout the various stages and types of
HFRS and to be closely correlated with the progression of HFRS as
well as the severity of kidney damage.44
7. Treatment and prevention of HFRS
The treatment of HFRS is based on the clinical symptoms of the
disease and occasionally includes haemodialysis, oxygenation, and
shock therapy. There is no speciﬁc therapy available. The use of
ribavirin, an antiviral agent, has resulted in a reduction in
morbidity and a decrease in fatalities in HFRS patients in China.45
Other promising new ideas, including the use of a bradykinin
receptor antagonist (bradykinin is involved in vasodilatation and
increases vascular permeability) and passive immune therapy with
human plasma, have mainly been based on similar ﬁndings in the
hamster model, and have not been used widely in humans.46,47
Steroid-based anti-inﬂammatory treatment options have been
described in several case reports, particularly in patients with
Table 1
Laboratory methods used for hantavirus diagnostics in clinical practice
Methods Advantages Disadvantages Recommendation Ref.
Serological methods
ELISAs (IgM, IgG) Sensitive and speciﬁc
Cross-reactivity allows the detection of
unexpected hantaviruses
Low cost
Can be used during entire clinical
course
Do not allow serotyping Most commonly used
Positive later than RT-PCR
24–27
ICG test Rapid, sensitive, and speciﬁc
Low cost
Easy to perform (no need for special
equipment or trained staff)
Does not allow serotyping Commonly used
Cost-effective
28–30
IFA More speciﬁc than ELISAs Low sensitivity
Laborious
Uncommonly used 26,31,32
WB More sensitive and speciﬁc than ELISAs Expensive and laborious Uncommonly used 24–26,33
SIA More speciﬁc than WB Low sensitivity
Expensive and laborious
Uncommonly used 24–26
Neutralization test Allows serotyping Expensive and laborious
Needs a BSL-3 lab
Uncommonly used 25,26,34
Molecular methods
Real-time RT-PCR Rapid, high sensitivity and speciﬁcity
Quantitative assay
Expensive
Does not detect hantavirus
after viremic phase
Commonly used
Positive earlier than ELISAs
33,35
NGS Useful for virus discovery and
genotyping
Too expensive and complex Rarely used 36,37
Microarray Rapid, sensitive, and speciﬁc Too expensive and complex Rarely used 37
Others
IHC Detects hantavirus antigens in tissues Laborious Mostly used in biopsy or
post-mortem
38
Virus culture Allows further virological studies Low sensitivity
Expensive and laborious
Needs BSL-3 lab and trained staff
Rarely used 37,38
ELISA, enzyme-linked immunosorbent assay; RT-PCR, reverse transcription-polymerase chain reaction; ICG, immunochromatographic; IFA, immunoﬂuorescence assay; WB,
Western blot; SIA, strip immunoblot assay; BSL-3 lab, biological safety level 3 laboratory; NGS, next generation sequencing; IHC, immunohistochemistry.
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been no clinical trial to conﬁrm the beneﬁt of glucocorticoid
treatment.37
There are three types of vaccine for HFRS: killed vaccines, DNA
vaccines, and attenuated live vaccines. The latter two are still in
phase I and II clinical studies or pre-clinical studies.49,50 In
different countries and regions, the species of pathogenic
hantaviruses may be different, and speciﬁc vaccines may be
required for the different species. Several killed vaccines have
been generated by inactivation of hantavirus in the rodent brain
and from cell culture-derived hantaviruses, and a few of them are
commercially produced and licensed for use in humans, such as
Hantavax in Korea and the monovalent HTNV and SEOV vaccines,
as well as the bivalent HTNV/SEOV vaccines, in China.27,51–53
Large-scale human trials have been reported in China that have
demonstrated a protective efﬁcacy of 93.77–97.61% for the
inactivated monovalent vaccines54 and nearly 100% for
the inactivated bivalent vaccines.52 Hantavirus vaccines have
been used in China and Korea for years, while there are no licensed
vaccines available in any other regions,2 because there have been
no similar efforts for HFRS vaccine development in other regions.
One reason for this is that the incidence of HFRS in the regions
outside of China and Korea might be much lower. From a health
economics perspective, the vaccination is only provided to adults
in China in the areas where the incidence of HFRS is higher than
50/100 000 persons.55 Another reason might be that it is difﬁcult
to produce effective HFRS vaccines against local pathogenic
species of hantaviruses.56,57 Exposure prophylaxis is still the most
important approach to prevent hantavirus infections.37 Improv-
ing general awareness and knowledge of pathogen sources,
transmission routes (how to avoid contact with hantavirus),
housing conditions, good hygiene, and human migration from
rural areas to cities might contribute to the decline in HFRS.28. Spatiotemporal distribution of HFRS in China
Data on the reported HFRS cases and the monthly and annual
HFRS incidence in China from January 2004 to April 2015 were
obtained from the Chinese Centre for Disease Control and
Prevention (CDC). HFRS cases were ﬁrst diagnosed according to
clinical symptoms, then blood samples were collected in the
hospital and serological identiﬁcation was performed in the
laboratory of each provincial CDC to conﬁrm the clinical diagnosis.
The serologically conﬁrmed cases were collected. This study was
reviewed by the research institutional review board of the Xuzhou
Central Hospital and the China CDC. The review board concluded
that utilization of disease surveillance data did not require
oversight by an ethics committee.
9. Temporal distribution analyses
The numbers of monthly HFRS cases in China from January
2004 to April 2015, including the numbers of deaths, were
calculated and plotted to observe seasonal ﬂuctuations. The results
showed that the numbers of HFRS cases decreased sharply from
2004 to 2009, then increased markedly from 2010 to 2012, and
have decreased again since 2013. The numbers of HFRS cases were
found to vary seasonally; most cases occurred in the winter
(November to January) and early summer (May to July), and they
usually peaked in June and November. The numbers of deaths
revealed a similar trend (Figure 1).
10. Geographical information system (GIS) mapping for the
incidence of HFRS
To conduct a GIS-based analysis of the spatial distribution of HFRS,
a province-level map of China was obtained. The province-level point
Figure 1. Temporal distribution of HFRS in China from January 2004 to April 2015. The solid blue line represents the number of HFRS cases; the dashed orange line indicates
the number of HFRS mortality cases. Most cases occurred in the winter and early summer, usually in June and November.
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of central points of each province was created. To lessen variations,
the annual incidence of HFRS per 100 000 persons for each
province was calculated. The annual incidence of HFRS for eachFigure 2. Yearly distribution of HFRSprovince was mapped using a GIS technique and Mapinfo software
(Professional Version 12.0.2). Based on the average annual incidence,
the provinces were grouped into ﬁve categories: no data areas;
low endemic areas with an average annual incidence between 0 and incidence in China, 2005–2013.
L.-X. Zou et al. / International Journal of Infectious Diseases 43 (2016) 95–100 990.01/100 000 persons; medium endemic areas with an average
annual incidence between 0.01 and 1/100 000; higher endemic areas
with an average annual incidence between 1 and 5/100 000; and
highest endemic areas with an average annual incidence >5/
100 000. The ﬁve categories were colour-coded on the maps.
The HFRS incidence varied between the provinces (Figure 2). In
2005, Heilongjiang, Jilin, and Liaoning exhibited the highest
incidences, and Inner Mongolia, Hebei, Shandong, Shaanxi,
Zhejiang, and Jiangxi exhibited the second highest incidences.
The HFRS incidences in these provinces have tended to decline
since 2005, with the exception of the HFRS incidence in Shaanxi.
From 2010 to 2012, Shaanxi surpassed Heilongjiang and became
the province with the highest HFRS incidence.
Previous studies have revealed that climatic factors can
inﬂuence HFRS incidence through their effects on the reservoir
host and environmental conditions. However, climatic changes are
mainly associated with global climate patterns, usually indicated
by the multivariate El Nin˜o Southern Oscillation (ENSO) index
(MEI), and are difﬁcult to control by government measures.58 Thus,
the HFRS incidence in northeast China (a traditional epidemic area)
has declined since 2005, mainly due to rodent control measures,
improvements in the environment, and effective vaccination
programmes.
11. Conclusions
Hantavirus infection and HFRS should be suspected in patients
with symptoms of acute renal failure, fever, haemorrhage,
headache, and abdominal/back/orbit pain, who live in rural areas
or who have had possible rodent exposure within the last 7 weeks.
A timely diagnosis requires serological tests to detect the IgM/IgG
antibodies of hantaviruses, combined with RT-PCR and new
biomarkers. These biomarkers may be correlated with the disease
severity of HFRS. Increasing our knowledge of the pathogenesis
and renal pathology will contribute to our understanding of the
mechanisms of vascular leakage and kidney damage, which will
help in the proper treatment of the severe forms of HFRS. No
speciﬁc therapy is in use in China, and well-planned randomized
controlled trials are needed to develop new treatment measures.
There is an urgent need to generate vaccines with a higher degree
of cross-reactivity for the diversity of hantavirus species.
Epidemiological surveillance of communicable diseases is one
of the most traditional health-related activities. This article
provides the latest data on the geographical distribution, yearly
trends, and seasonal trends in HFRS in mainland China, which will
help to increase our understanding of the factors inﬂuencing
hantavirus infection and provide valuable information for the
hygiene authorities to design and implement effective measures
for the control and prevention of HFRS in China.
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